38532858|t|Anthranilic Acid, a GPR109A Agonist, and Schizophrenia.
38532858|a|Introduction: Limited clinical efficiency of current medications warrants search for new antipsychotic agents. Deorphanized G-protein coupled receptor (GPR)109A has not attracted much of attention of schizophrenia researchers. We analyzed literature and our data on endogenous agonists of GPR109A, beta-hydroxybutyrate (BHB), anthranilic (AA), butyric (BA), and nicotinic (NA) acids, in individuals with schizophrenia. Data: Sex specific differences: plasma AA levels were 27% higher in female than in male patients and correlated with PANSS before 6 weeks of antipsychotics treatment (r = .625, P < .019, Spearman's test). There was no sex specific differences of plasma AA levels after treatment. AA plasma levels inversely correlated (-.58, P < .005) with PANSS scores in responders to treatment (at least, 50% improvement) but not in nonresponders. Preclinical studies suggested antipsychotic effect of BHB and BA. Clinical studies observed antipsychotic effect of NA; benzoate sodium, an AA precursor; and interventions associated with BHB upregulation (eg, fasting and ketogenic diets). Discussion: Upregulation of GPR109A, an anti-inflammatory and neuroprotective receptor, inhibits cytosolic phospholipase A2 (cPLA2), an enzyme that breakdown myelin, lipid-based insulating axonal sheath that protects and promotes nerve conduction. Brain cPLA2 is upregulated in individuals with schizophrenia and subjects at high-risk for development of psychosis. Lower myelin content is associated with cognitive decline in individuals with schizophrenia. Therefore, GPR109A might exert antipsychotic effect via suppression of cPLA2, and, consequently, preservation of myelin integrity. Future research might explore antipsychotic effects of (1) human pegylated kynureninase, an enzyme that catalyzes formation of AA from kynurenine (Kyn); (2) inhibitors of Kyn conversion into kynurenic acid, for example, KYN5356, to patients with already impaired Kyn conversion into 3-hydroxykynurenine; (3) synthetic GPR 109A agonists, for example, MK-1903 and SCH900271 and GSK256073, that underwent clinical trials as anti-dyslipidemia agents. GPR109A expression, that might be a new endophenotype of schizophrenia, especially associated with cognitive impairment, needs thorough assessment.
38532858	0	16	Anthranilic Acid	Chemical	MESH:C031385
38532858	20	27	GPR109A	Gene	338442
38532858	41	54	Schizophrenia	Disease	MESH:D012559
38532858	256	269	schizophrenia	Disease	MESH:D012559
38532858	345	350	GPR10	Gene	338442
38532858	347	352	R109A	ProteinMutation	tmVar:p|SUB|R|109|A;HGVS:p.R109A;VariantGroup:0
38532858	354	374	beta-hydroxybutyrate	Chemical	MESH:D020155
38532858	376	379	BHB	Chemical	MESH:D020155
38532858	382	393	anthranilic	Chemical	-
38532858	395	397	AA	Chemical	-
38532858	400	407	butyric	Chemical	-
38532858	409	411	BA	Chemical	MESH:D001464
38532858	418	438	nicotinic (NA) acids	Chemical	-
38532858	460	473	schizophrenia	Disease	MESH:D012559
38532858	514	516	AA	Chemical	-
38532858	563	571	patients	Species	9606
38532858	728	730	AA	Chemical	-
38532858	755	757	AA	Chemical	-
38532858	963	966	BHB	Chemical	MESH:D020155
38532858	971	973	BA	Chemical	MESH:D001464
38532858	1025	1027	NA	Chemical	MESH:D012964
38532858	1029	1044	benzoate sodium	Chemical	MESH:D020160
38532858	1049	1051	AA	Chemical	-
38532858	1097	1100	BHB	Chemical	MESH:D020155
38532858	1177	1184	GPR109A	Gene	338442
38532858	1194	1206	inflammatory	Disease	MESH:D007249
38532858	1246	1272	cytosolic phospholipase A2	Gene	5321
38532858	1274	1279	cPLA2	Gene	5321
38532858	1315	1320	lipid	Chemical	MESH:D008055
38532858	1403	1408	cPLA2	Gene	5321
38532858	1444	1457	schizophrenia	Disease	MESH:D012559
38532858	1503	1512	psychosis	Disease	MESH:D011618
38532858	1554	1571	cognitive decline	Disease	MESH:D003072
38532858	1592	1605	schizophrenia	Disease	MESH:D012559
38532858	1618	1625	GPR109A	Gene	338442
38532858	1678	1683	cPLA2	Gene	5321
38532858	1797	1802	human	Species	9606
38532858	1865	1867	AA	Chemical	-
38532858	1873	1883	kynurenine	Chemical	MESH:D007737
38532858	1885	1888	Kyn	Chemical	MESH:D007737
38532858	1909	1912	Kyn	Chemical	MESH:D007737
38532858	1929	1943	kynurenic acid	Chemical	MESH:D007736
38532858	1958	1965	KYN5356	Chemical	-
38532858	1970	1978	patients	Species	9606
38532858	2001	2004	Kyn	Chemical	MESH:D007737
38532858	2021	2040	3-hydroxykynurenine	Chemical	MESH:C005045
38532858	2056	2060	GPR 	Gene	338442
38532858	2060	2064	109A	ProteinMutation	tmVar:c|Allele|A|109;VariantGroup:0
38532858	2088	2095	MK-1903	Chemical	MESH:C573553
38532858	2100	2109	SCH900271	Chemical	-
38532858	2114	2123	GSK256073	Chemical	MESH:C000604188
38532858	2164	2176	dyslipidemia	Disease	MESH:D050171
38532858	2185	2192	GPR109A	Gene	338442
38532858	2242	2255	schizophrenia	Disease	MESH:D012559
38532858	2284	2304	cognitive impairment	Disease	MESH:D003072
38532858	Positive_Correlation	MESH:C573553	VariantGroup:0;tmVar:c
38532858	Positive_Correlation	MESH:C000604188	HGVS:p.R109A
38532858	Positive_Correlation	MESH:C000604188	VariantGroup:0;tmVar:c
38532858	Negative_Correlation	MESH:C000604188	MESH:D050171
38532858	Negative_Correlation	MESH:C573553	MESH:D050171
38532858	Negative_Correlation	338442	5321
38532858	Association	MESH:D050171	VariantGroup:0;tmVar:c
38532858	Positive_Correlation	MESH:C000604188	338442
38532858	Association	MESH:D012559	338442
38532858	Positive_Correlation	MESH:C573553	HGVS:p.R109A
38532858	Association	MESH:C031385	MESH:D012559
38532858	Association	MESH:D011618	5321
38532858	Positive_Correlation	MESH:C031385	338442
38532858	Negative_Correlation	MESH:D007249	338442
38532858	Association	MESH:D012559	VariantGroup:0;tmVar:c
38532858	Association	MESH:D050171	HGVS:p.R109A
38532858	Association	MESH:C005045	MESH:D007737
38532858	Positive_Correlation	MESH:C573553	338442
38532858	Positive_Correlation	MESH:D012559	5321

